A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma-Reference-Cited by-同舟云学术

A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma

Published:2012-06-06 Issue:137 Volume:4 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sivanand Sharanya¹²³,Peña-Llopis Samuel¹²³,Zhao Hong³,Kucejova Blanka¹²³,Spence Patrick¹²³,Pavia-Jimenez Andrea¹²³,Yamasaki Toshinari¹²³,McBride David J.⁴,Gillen Jessica¹²³,Wolff Nicholas C.¹²³,Morlock Lorraine⁵,Lotan Yair⁶,Raj Ganesh V.⁶,Sagalowsky Arthur⁶,Margulis Vitaly⁶,Cadeddu Jeffrey A.⁶,Ross Mark T.⁴,Bentley David R.⁴,Kabbani Wareef⁷,Xie Xian-Jin³,Kapur Payal⁷,Williams Noelle S.⁵,Brugarolas James¹²³

Affiliation:

1. Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

2. Department of Internal Medicine, Oncology Division, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

3. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

4. Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Essex CB10 1XL, UK.

5. Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

6. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

7. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Abstract

Extensively validated tumorgraft model shows activity of investigational agent dovitinib against renal cell carcinoma.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference70 articles.

1. Can the pharmaceutical industry reduce attrition rates?

2. Preclinical development of molecular-targeted agents for cancer

3. Anticancer drug development: the grand challenges

4. 50 Years of preclinical anticancer drug screening: Empirical to target-driven approaches.;Suggitt M.;Clin. Cancer Res.,2005

5. A Blueprint for Advancing Genetics-Based Cancer Therapy

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioinformatics analysis to disclose shared molecular mechanisms between type-2 diabetes and clear-cell renal-cell carcinoma, and therapeutic indications;Scientific Reports;2024-08-19

2. Unconventional mechanism of action and resistance to rapalogs in renal cancer;Proceedings of the National Academy of Sciences;2024-06-11

3. Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor;BMC Cancer;2024-04-17

4. Von Hippel Lindau tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis;Journal of Clinical Investigation;2024-04-15

5. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis;Journal of Clinical Investigation;2024-02-22